Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Scancell-led team short-listed for award

The Cancer Research UK Grand Challenge is a prestigious award that brings with it significant funding
woman at microscope
The scientists are aiming to identify the most effective treatments for patients with most strains of the disease

A team led by Scancell Holdings Plc’s (LON:SCLP) chief scientific officer that is pioneering a vaccine-led approach to tackling tumours has been shortlisted for  a £20mln award.

Professor Lindy Durrant is teaming up with researchers from Genentech, BioNtech and ISA Pharmaceuticals to develop Project Blueprint.

The scientists are aiming to identify the most effective treatments for patients with most strains of the disease.

However the focus, at least initially, will be on head, neck lung, and pancreatic cancers as well as, glioblastoma - all of which currently have a poor prognosis.

Modi-3 may play a role

As part of the programme, Durrant’s team will consider whether Scancell’s Modi-3 product has a role to play.

Project Blueprint has been shortlisted for the Cancer Research UK Grand Challenge, a prestigious award that brings with it £20mln of funding.

Last year four teams won financial backing from the charity.

READ: Scancell eyeing investigational new drug application for SCIB1 in first half

Durrant said: “This brings us one step closer to delivering our cancer vaccine blueprint. 

“We believe this approach will provide an effective, novel therapy and facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer. 

“Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space."

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use